Investors

MolMed signs a multi-year agreement and announces the beginning of a new collaboration in the field of T cell therapies.
MolMed signs a multi-year agreement and announces the beginning of a new collaboration in the field of T cell therapies. ▾

News & Events

Stay update
February 24-27, 2020 London, UK - CAR-TCR Summit Europe ▾

February 24-27, 2020 London, UK - CAR-TCR Summit Europe

The CAR-TCR Summit Europe will be held from February 24 to 27, 2020 in London, United Kingdom.

 

Dr. Luca Alberici, MolMed's Chief Business Officer, will present MolMed activity discussing about development, clinical and commercial GMP supply of next generation Vectors and cell therapies on February 25 at 8:30 AM GMT.

Follow the event at the link https://cartcr-europe.com/

Investors

MolMed: the CAR-T CD44v6 clinical trial progress presented at the 2nd European CAR T Cell Meeting in Sitges, Barcelona.
MolMed: the CAR-T CD44v6 clinical trial progress presented at the 2nd European CAR T Cell Meeting in Sitges, Barcelona. ▾

News & Events

Stay update
MolMed attending the 2nd European CAR T Cell Meeting di Sitges, Barcellona, with an update on the CAR T CD44v6 clinical trial ▾

MolMed attending the 2nd European CAR T Cell Meeting di Sitges, Barcellona, with an update on the CAR T CD44v6 clinical trial